NUVL Company Profile and Key Details

NUVL has shown sold momentum, gaining 6.83% over the past week and 14.49% over the past quarter, though year-to-date performance is up 5.31%. Short-term trend indicators are mixed aligned (SMA20 0.76%, SMA50 0.41%, SMA200 16.26%). The stock’s 14-day RSI is 51.07 (neutral), while the ATR of 4.47 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -8.04% below its high and over 87.14% above its low. Average 10-day trading volume of 9.83 million shares is significantly above the 3-month average of 1.50 million, indicating heightened recent market interest.

Nuvalent, Inc. has 66.67 million shares outstanding. The public float is 41.56 million shares, elevated short interest at 17.88% of float. This equals 5.54 million shares. The short ratio is 11.1 days. Institutional investors hold 112.31% of the float. Insiders own 2.84%. Flynn James E holds 8.30 million shares, Hack Andrew A. F. has 1.45 million shares and Porter James Richard has 324.88 thousand shares. Over the past six months, insider transactions show net selling. They sold 53.06 thousand shares across 35 transactions.

Nuvalent, Inc. (NASDAQ:NUVL) closed at $123.25 USD, gaining $34.76 (39.28%) from the previous close of $88.49. The stock is currently trading near its 52-week high $71.13 and $123.62. With a market capitalization of about $9.07 billion, Nuvalent, Inc. is classified as a mid-cap and shows market-like volatility (beta ~1.15). Key stats such as the average daily volume over the past year has been around 670.99 thousand shares, trading with heavier-than-usual volume. Headquartered in Cambridge, MA, Nuvalent, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO James R. Porter, the company employs approximately 162 people and listed since July 29, 2021. Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer.

Nuvalent, Inc. generated EPS of -$5.32 over the past year. Five-year average earnings growth is -74.22%. Wall Street analysts project EPS growth of -2.52% annually over the next five years. The latest quarter delivered EPS of -$1.39. The next quarter is forecast at -$1.48. Next year's EPS is expected at -$33.16. Analyst sentiment is bullish. Analyst rating data shows there are 16 Strong Buy ratings, 11 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $189.00 to $105.00. The high target offers 53.35% upside. The low target suggests -14.81% downside. The mean target is $132.67. This offers 7.64% upside. Nuvalent, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 07, 2026, missed forecasts by 2.96%. The prior quarter beat by -12.84%. Over the last six quarters, Apple has recorded several small beats. These include 0.96% in February 27, 2025.

Nuvalent, Inc. trades at a P/E ratio of -21.52, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 8.25 trading at moderately above to book value. The P/FCF stands at -28.95, also below market averages.

Our AI price prediction model suggests that Nuvalent, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -30.41%, with price expected at $85.77 by June 22, 2026, within a range of $81.12 to $90.75 3-Month Outlook: Projected fall of -42.81%, reaching $70.49 by September 04, 2026, with a range of $67.85 to $72.79. 1-Year Outlook: Projected loss of -1.05%, with price at $121.95 by June 09, 2027, within a range of $117.26 to $125.76.

Nuvalent, Inc. (NASDAQ:NUVL) shares are flat 5.31% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Nuvalent, Inc. trading at a premium to the broader market with a P/E of -21.52. Analyst sentiment is cautious, with the majority of ratings in Equal-Weight territory and a mean price target of $114.09, suggesting -7.43% downside. Our AI forecast model points to short-term weakness (-30.41% over two weeks), a medium-term fall (-42.81% over three months), and a longer-term loss (-1.05% over one year), with expected trading ranges indicating moderate volatility.

Nuvalent, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $3.60. This means the shares are trading above this model’s fair value.